aTyr Pharma (LIFE) Set to Announce Quarterly Earnings on Wednesday

aTyr Pharma (NASDAQ:LIFE) is scheduled to be announcing its earnings results on Wednesday, March 14th.

aTyr Pharma (NASDAQ LIFE) opened at $3.00 on Tuesday. aTyr Pharma has a 12-month low of $2.30 and a 12-month high of $6.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.49 and a current ratio of 9.49. The firm has a market capitalization of $89.28, a PE ratio of -1.48 and a beta of 3.54.

A number of research analysts have recently weighed in on the company. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. cut aTyr Pharma from a “neutral” rating to an “underweight” rating in a research report on Wednesday, February 14th. Finally, ValuEngine cut aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. aTyr Pharma presently has an average rating of “Hold” and a consensus target price of $4.56.

COPYRIGHT VIOLATION NOTICE: “aTyr Pharma (LIFE) Set to Announce Quarterly Earnings on Wednesday” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Earnings History for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.

Leave a Reply